The AMPK/ACC/CPT1 pathway and the AMPK/SREBP1/Scd1 pathway may be potential targets for the prevention of hepatic lipid deposition and the treatment of NAFLD. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.